Skip to main content

Press Releases and Ad-hoc Announcements

06 November 2024	PR: Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024	PDF
24 October 2024	PR: Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024	PDF
10 October 2024	PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024	PDF
11 July 2024	PR: Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business	PDF
21 June 2024	PR: Heidelberg Pharma reports on the results of the Annual General Meeting 2024	PDF
18 June 2024	AH: Heidelberg Pharma AG Announces Updated Guidance	PDF
23 May 2024	PR: Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024	PDF
25 April 2024	PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024	PDF
05 April 2024	PR: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR	PDF
27 March 2024	PR: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101	PDF
25 March 2024	PR: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023	PDF
19 March 2024	PR: Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty	PDF
18 March 2024	PR: Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study	PDF
06 March 2024	PR: Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024	PDF
04 March 2024	PR: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million	PDF
04 March 2024	AH: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million	PDF